RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https://www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320